BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Cell Therapy
    • COVID-19
    • CAR-T
    • Cord Blood
  • Exosomes
  • Interviews
  • News
    • Press Releases
    • Job Posts
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » Coronavirus » Page 2

Capricor Treats Two COVID-19 Patients with Cardiosphere-Derived Cells (CAP-1002)

April 21, 2020 By Cade Hildreth (CEO)

capricor covid19

Capricor Initiates Compassionate Use Program for Severe COVID-19 Patients using CAP-1002, its Novel Cell Therapy.

LOS ANGELES, April 03, 2020 — Capricor Therapeutics (NASDAQ: CAPR) a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment or prevention of serious diseases, announced it is providing CAP-1002, its novel cell therapy to patients with advanced COVID-19 under the compassionate use pathway. [Read more…]

Filed Under: Coronavirus (COVID-19), Press Releases, Stem Cell News Tagged With: Coronavirus

NantKwest, ImmunityBio Advance BM-MSCs, NK Cell Therapies & Vaccines Against COVID-19

April 20, 2020 By Cade Hildreth (CEO)

Nantkwest ImmunityBio COVID-19

Immunotherapy companies led by Dr. Patrick Soon-Shiong are developing potential coronavirus therapeutics and vaccines to address the evolving stages of disease from moderate infection to severe acute respiratory distress syndrome (SARS).

  • Therapeutic for Severe and Critically Ill COVID-19 Patients on Ventilator Support:
    • NantKwest’s MSCs: Bone marrow-derived mesenchymal stem cells (MSC) to mitigate ‘cytopathic storm’ [Read more…]

Filed Under: Coronavirus (COVID-19) Tagged With: Coronavirus

Cure Alliance Launches 24-Patient Trial Using UC-MSCs Against COVID-19 Complications

April 17, 2020 By Cade Hildreth (CEO)

The Cure Alliance COVID-19 Trial

FDA Authorizes Cure Alliance Rxperts to Test UC-MSCs

THE CURE ALLIANCE, April 9, 2020 — After a lightening round of proposals and reviews, an international team of scientists led by Dr. Camillo Ricordi was granted immediate FDA authorization for a 24-patient clinical trial to test the safety and exploratory efficacy of umbilical cord-derived mesenchymal stem cells (UC-MSCs) to block the life-threatening lung inflammation that accompanies severe cases of COVID-19. [Read more…]

Filed Under: Coronavirus (COVID-19) Tagged With: Coronavirus

Orbsen’s COVID-19 Trial To Test Stromal Cell Immunotherapy Against ARDS

April 13, 2020 By Cade Hildreth (CEO)

Orbsen’s stromal cell immunotherapy, ORBCEL, may benefit patients with Acute Respiratory Distress Syndrome (ARDS) caused by coronavirus (COVID-19).

08 Apr, 2020, GALWAY, Ireland, April 8, 2020 — Orbsen Therapeutics, a biotechnology company focused on the development and commercialization of best-in-class stromal cell immunotherapies, announced the beginning of a phase 2a clinical trial for the treatment of COVID-19 patients with acute respiratory distress syndrome (ARDS). Nearly 90 percent of deaths caused by COVID-19 are the result of ARDS.

[Read more…]

Filed Under: Coronavirus (COVID-19) Tagged With: Coronavirus

COVID-19 Diagnostic Kits: Total Number, Types and Speed

April 10, 2020 By Cade Hildreth (CEO)

COVID-19 Diagnostic Kits

As of today, 41 laboratory COVID-19 diagnostic tests have been authorized by regulators to identify the virus. In the U.S., these tests are supplied by the CDC for the state and local public health departments and private medical providers are getting tests developed by the commercial manufacturers. The U.S. government did not issue guidance allowing commercial labs to process COVID-19 tests until February 29, 2020, after which the companies began testing within a week.

Currently, 20 COVID-19 diagnostic kits from the U.S. manufacturers have won the emergency use authorization (EUA) from the FDA. [Read more…]

Filed Under: Cord Blood Tagged With: Coronavirus

  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next Page »

Let’s Get Social

  • Facebook
  • Twitter
  • Instagram
  • Pinterest
  • LinkedIn

Nanocellect

Marathon Products

Menu
  • Blog
  • Stem Cell News
    • Press Releases
  • Stem Cells
    • HSCs
    • iPS Cells
    • MSCs
    • Neural Stem Cells
    • Adipose SCs
  • Exosomes
  • Cell Therapy
    • CAR-T
  • Cord Blood
  • Interviews

Cart

Top Rated Products

  • US Cord Blood and Cord Tissue Storage Rates Rates of U.S. Cord Blood and Cord Tissue Storage - Historical and Projected
    Rated 0 out of 5
    $197
  • Job Posting on BioInformant Job Posting on BioInformant.com - Your Perfect Hire Is In Our Audience
    Rated 0 out of 5
    $297
  • BioInformant Audience Reach BioInformant's Audience with Your Press Announcement
    Rated 0 out of 5
    $397 $297
My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2021 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: [email protected] | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.